Medical Condition

multiple myeloma

Total Trials

54

Recruiting Now

54

Trial Phases

Phase 2, Phase 1, Phase 2, Phase 4

ClinicalMetric tracks all active clinical trials for multiple myeloma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
Phase 1–4 studies from early safety trials to post-marketing surveillance
NIH, pharmaceutical sponsor, and academic medical center studies worldwide
AI-powered plain-language summary available for every trial listing

Frequently Asked Questions — multiple myeloma Clinical Trials

How many clinical trials are currently recruiting for multiple myeloma?

ClinicalMetric currently tracks 54 actively recruiting clinical trials for multiple myeloma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 54. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for multiple myeloma?

multiple myeloma research spans Phase 1 (16 trials), Phase 2 (22 trials), Phase 3 (4 trials), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a multiple myeloma clinical trial?

Eligibility criteria for multiple myeloma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Phase 4

Top Sponsors

Institute of Hematology & Blood Diseases Hospital, China 3 trials

Washington University School of Medicine 3 trials

Janssen Research & Development, LLC 2 trials

Regeneron Pharmaceuticals 2 trials

Xuzhou Medical University 2 trials

multiple myeloma

Frequently Asked Questions — multiple myeloma Clinical Trials

Recruiting Clinical Trials

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)

BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Sleep Apnea in Patients With MGUS and MM

Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma

Study of BMS-986453 in Newly Diagnosed Multiple Myeloma

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid

Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma

IMMUNOPLANT for Newly Diagnosed Multiple Myeloma

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma

Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment

The Ambient Light Multiple Myeloma Study

Examination of Vertebroplasty in Addition to Regular Treatment of Patients With Multiple Myeloma.

Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)

Evaluation of a PREHABilitation Protocol Using Adapted Physical Activity (APA) for Multiple Myeloma Patients Eligible for Intensive Autologous Stem Cell Transplantation Treatment

A Cross-sectional Study on the Positive Rate of M Protein Based on a Highly Sensitive Serum M Protein Detection Method.

Registry for Adults With Plasma Cell Disorders (PCD's)

a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

GMMG Multiple Myeloma Registry

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Mozobil for Autologous Hematopoietic Stem Cell Transplantation

A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers

18F-Fluciclovine PET/CT in Multiple Myeloma

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

A Clinical Study of SHR-9539 in Patients With Multiple Myeloma

Integrative Therapies in Multiple Myeloma

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation.

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

Institut Paoli Calmettes Multiple Myeloma Database

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone

Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients

Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study

Collection of Samples and Clinical Data From Patients With Amyloid Diseases

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma

Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma

Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma